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The liver is the major organ involved in
drug and toxicant metabolism and as such
is one of the main targets for the adverse
effects of such substances (Mitchell et al.
1976; Zimmerman 1976). Hepatic toxicity
is the most common single adverse effect
leading to label warnings, use restrictions,
and market withdrawals for pharmaceuti-
cals (CDER-PhRMA-AASLD 2000).
Consequently, evaluating the toxicity of
new drugs and chemicals involves assess-
ment of the livers of exposed animals for
adverse end points. These end points are
biological markers (biomarkers) such as
histopathology and measuring of serum
chemistry parameters and are used to quan-
titatively measure any deleterious effects of
a toxicant to an organism or individual.
Although traditional experimental
approaches and biomarkers used for pre-
clinical safety assessment can reveal dose-
dependent hepatic toxicity in animal
models, they rarely provide an indication
of toxic mechanism and are equivocal
predictors for potential human responses.
As a result of recent technological
advances in molecular biology, one of the
more important developments in the
biomarker field has been the realization
that gene expression proﬁles obtained using
microarrays may be useful biomarkers for
evaluating toxicity in animal models. To
date, specific gene expression profiles have
been evaluated for several types of toxico-
logical studies including a) identifying
exposure to speciﬁc chemical classes such as
aryl hydrocarbon receptor agonists, cyto-
toxic anti-inflammatory agents, DNA-
damaging agents, enzyme inducers,
hypoxia-inducing agents, noncoplanar
polychlorinated biphenyls (PCBs), and per-
oxisome proliferators (Burczynski et al.
2000; Hamadeh et al. 2002a; Thomas
et al. 2001); b) identifying toxic end
points, for example, histopathology, clini-
cal chemistry (Waring et al. 2001b); c) pre-
dicting or classifying exposures that later
produce a toxic outcome (Kier and Nolan
2003); and d) identifying mechanisms of
toxicity (Waring et al. 2001a). Thus, it is
apparent that gene expression profiles can
play a key role in the risk characterization
component of the risk assessment and
management process.
The use of genomic biomarkers to
evaluate toxic effects has been termed “tox-
icogenomics.” Although originally viewed
as the use of genomic data to interpret and
understand toxicological ﬁndings, the deﬁ-
nition of toxicogenomics has gradually
evolved to encompass other fields. One
commonly used definition of toxico-
genomics is as follows:
a scientific field that elucidates how the entire
genome is involved in biological responses of
organisms exposed to environmental toxicants/
stressors. Toxicogenomics combines informa-
tion from studies of genomic-scale mRNA pro-
filing (by microarray analysis), cell-wide or
tissue-wide protein profiling (proteomics),
genetic susceptibility, and computational mod-
els to understand the roles of gene-environment
interactions in disease. (National Center for
Toxicogenomics 2000)
To identify and address some of the
issues, challenges, and opportunities
encountered by the use of toxicogenomics
in the context of risk assessment, the
Health and Environmental Sciences
Institute (HESI) of the International Life
Sciences Institute (ILSI, http://hesi.ilsi.
org/) formed a project committee to
develop a collaborative scientific program
to study these areas [see Pennie et al.
(2004), this mini-monograph]. The
Technical Committee on the Application
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DNA microarrays and related tools offer promise for identiﬁcation of pathways involved in toxic
responses to xenobiotics. To be useful for risk assessment, experimental data must be challenged
for reliability and interlaboratory reproducibility. Toward this goal, the Hepatotoxicity Working
Group of the International Life Sciences Institute (ILSI) Health and Environmental Sciences
Institute (HESI) Technical Committee on Application of Genomics to Mechanism-Based Risk
Assessment evaluated and compared biological and gene expression responses in rats exposed to
two model hepatotoxins—clofibrate and methapyrilene. This collaborative effort provided an
unprecedented opportunity for the working group to evaluate and compare multiple biological,
genomic, and toxicological parameters across different laboratories and microarray platforms.
Many of the results from this collaboration are presented in accompanying articles in this mini-
monograph, whereas others have been published previously. In vivo studies for both compounds
were conducted in two laboratories using a standard experimental protocol, and RNA samples
were distributed to 16 laboratories for analysis on six microarray platforms. Histopathology, clini-
cal chemistry, and organ weight changes were consistent with reported effects. Gene expression
results demonstrated reasonable agreement between laboratories and across platforms.
Discrepancies in expression proﬁles of some individual genes were largely due to platform differ-
ences and approaches to data analysis rather than to biological or interlaboratory variability.
Despite these discrepancies there was overall agreement in the biological pathways affected by
these compounds, demonstrating that transcriptional proﬁling is reproducible between laborato-
ries and can reliably identify affected pathways necessary to provide mechanistic insight. This
effort represents an important ﬁrst step toward the use of transcriptional proﬁling in risk assess-
ment. Key words: clofibrate, gene expression profiling, liver, methapyrilene, microarray, qRT-
PCR, rat, toxicogenomics. Environ Health Perspect 112:423–427 (2004). doi:10.1289/txg.6675
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Assessment was divided into several work
groups conducting large-scale cross-labora-
tory studies in hepatotoxicity, nephrotoxic-
ity, and genotoxicity. 
The Hepatotoxicity Working Group
(HWG) comprised representatives from 25
companies or subsidiaries, the U.S.
Environmental Protection Agency, U.S.
Air Force, the National Institute of
Environmental Health Sciences (NIEHS)
and the University of Surrey in England
(Table 1). 
The goal of the HWG was to evaluate
and compare biological, gene, and protein
expression responses in rats exposed to
well-studied hepatotoxins, using a standard
experimental protocol and to address the
following questions: 
• How comparable are the biological and
gene expression data from different labo-
ratories conducting in vivo studies?
• How reproducible is the data generated
across laboratories using the same
microarray platforms?
• How do data compare using different
microarray platform?
• How do data compare using RNA from
pooled and individual animals?
• Do the gene expression changes demon-
strate time/dose-dependent responses that
correlate with known biological markers
of toxicity? 
To this end, members of the HWG
developed standard experimental protocols
for two prototypical hepatotoxicants:
methapyrilene and clofibrate. Metha-
pyrilene, a histamine H1 receptor blocking
agent (Noguchi 1992), produces periportal
necrosis in rats (Steinmetz et al. 1988), and
is a nongenotoxic hepatocarcinogen in rats
(Mirsalis 1987). The hypolipidemic agent
clofibrate signals through the peroxisome
proliferator-activated receptor-alpha
(PPAR-α) to induce the proliferation of
hepatic peroxisomes [reviewed by Greene
(1995)]. Cloﬁbrate produces hepatomegaly
and is a nongenotoxic hepatocarcinogen in
rodents (Reddy and Qureshi, 1979;
von Daniken et al. 1981).
Experimental Overview
Pilot study. Before conducting full-scale
studies, we conducted a pilot study for an
estimate of interlaboratory variation in
results from the same RNA sample using a
single microarray platform. A reference
RNA sample was generated from the liver
of male Sprague-Dawley rats treated with
the high dose of cloﬁbrate (250 mg/kg/day)
or vehicle control for 3 days at Abbott
Laboratories(Abbott Park, IL). RNA samples
from three individual animals from each
group were pooled and distributed to five
laboratories for analysis using Affymetrix
(Santa Clara, CA) microarrays. Analysis of
the data using multidimensional scaling indi-
cated that the results tended to segregate by
site of analysis (Figure 1). Nevertheless, pro-
ﬁles within each laboratory were always quite
distinct between treated and control samples
and on the whole, data from control samples
tended to segregate away from the data from
treated samples. This pilot study served as a
basis for full-scale studies.
Full-scale studies. The in vivo dosing
phase for the full-scale studies was
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Table 1. List of companies participating in the HESI Hepatotoxicity Working Group.
Company name Location
Abbott Laboratories Abbott Park, IL, USA
Air Force Research Laboratory  Wright-Patterson AFB, OH, USA
Amgen Inc. Thousand Oaks, CA, USA
AstraZeneca Pharmaceuticals Macclesﬁeld, UK
AstraZeneca R&D Charnwood Loughborough, UK
Aventis Pharmaceuticals Bridgewater, NJ, USA
Collegeville, PA, USA
Vitry sur Seine Cedex, France
Bayer CropScience Wuppertal, Germany
Berlex Laboratories, Inc. Montville, NJ, USA
Biogen, Inc. Cambridge, MA, USA
Boehringer-Ingelheim Pharmaceuticals, Inc. Ridgeﬁeld, CT, USA
Boehringer-Ingelheim Pharma KG Biberach an der Riss, Germany
Bristol-Myers Squibb Co. Pennington, NJ, USA
Bristol-Myers Squibb Princeton, NJ, USA
Eisai Co., Ltd. Ibaraki, Japan
Tsukuba, Japan
Eisai Research Institute Wilmington, MA, USA
GlaxoSmithKline Research Triangle Park, NC, USA
Ware, UK
Hoffman-La Roche Inc. Nutley, NJ, USA
F. Hoffmann-La Roche Basel, Switzerland
Johnson & Johnson PRD, LLC Raritan, NJ, USA
Mitsubishi Pharma Corp.  Chiba, Japan
National Institute of Environmental Health Sciences Research Triangle Park, NC, USA
Novartis Pharma AG Basel, Switzerland
Pﬁzer Inc Groton, CT, USA
Rosetta Inpharmatics Kirkland, WA, USA
RW Johnson PRI Raritan, NJ, USA
Sankyo Co., Ltd. Shizuoka, Japan
Sanoﬁ-Synthélabo Pharmaceuticals, Inc. Malvern, PA, USA
Schering AG Berlin, Germany
Schering-Plough Research Institute Lafeyette, NJ, USA
Tanabe Seiyaku Co., Ltd. Saitama, Japan
The DuPont Co. Newark, DE, USA
Unilever Research Sharnbrook, Bedfordshire, UK
University of Surrey Guildford, UK
U.S. Environmental Protection Agency Research Triangle Park, NC, USA
Wyeth-Genetics Institute Andover, MA, USA
Wyeth-Ayerst Research Andover, MA, USA
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Figure 1. Multidimensional scaling plot of gene
expression data from a multisite analysis of a sin-
gle RNA sample. Abbreviations: AVE, Aventis
Pharmaceuticals; AZN, AstraZeneca Pharma-
ceuticals; PFE, Pfizer Inc; RO, F. Hoffmann-
La Roche Inc.; Cont, pooled RNA from control
animals; Trt, pooled RNA from treated animals. In
a pilot study, microarray data using Affymetrix
microarrays were generated at ﬁve different labo-
ratory sites using RNA pooled from three control
rats compared with RNA pooled from three cloﬁ-
brate-treated rats. This ﬁgure represents a single
multidimensional scaling analysis of these data,
and illustrates clustering (dashed ovals) of the
control and treated samples by laboratory.
Clustering in this manner was thought to be due to
technical variations between sites rather than bio-
logical differences and provided a preliminary look
at the difficulties to be encountered in the full-
scale studies. However, within all-site–clusters
there was a clear distinction between RNAs
derived from control and treated animals, and all
sites showed the same biological effect of treat-
ment in the form a shift down the y axis (arrows).
Figure contributed by Michael Lawton, Pﬁzer Inc,
and reproduced with permission. conducted in two different laboratories for
each test compound, using identical proto-
cols and test compound. Further details of
these studies are provided in the articles by
Baker et al. (2004); Chu et al. (2004); and
Waring et al. (2004) elsewhere in this
mini-monograph. Methapyrilene was
administered at 0, 10 or 100 mg/kg/day by
gavage for 1, 3, and 7 days (Abbott
Laboratories; Boehringer-Ingelheim
Pharmaceuticals, Inc., Ridgefield, CT).
Clofibrate was administered at doses of
0, 25, or 250 mg/kg/day by gavage for
1, 3, and 7 days (Abbott Laboratories;
GlaxoSmithKline (GSK; Hertfordshire,
UK). For both compounds, the high dose
levels were selected based on reports indi-
cating that they would elicit hepatotoxicity
without the introduction of secondary
pathologies such as inﬂammation that that
might severely influence gene expression
data (clofibrate, Karbowski et al. 1999;
methapyrilene, Graichen et al. 1985). The
low doses were selected as one-tenth of the
hepatotoxic dose and at which no gross
hepatotoxic effect was anticipated. Total
RNA samples from treated and control ani-
mals (both pooled (n = 4) and individual)
were distributed to members of the HWG
for analysis on different microarray plat-
forms (Table 2). Clofibrate samples were
analyzed at 16 sites using six different
platforms; methapyrilene samples were
analyzed at 12 sites using six different plat-
forms. Because most research groups
analyze microarray data differently using
different algorithms, each site was requested
to analyze data according to its own
in-house procedures. 
qRT-PCR analysis. To investigate the
source of certain discrepancies in direction
of gene change between two different
microarray platforms (Affymetrix and
Incyte [Palo Alto, CA]), quantitative
reverse transcriptase–polymerase chain
reaction (qRT–PCR) and in silico sequence
analyses were performed for selected genes.
Further details are provided in the article
by Goodsaid et al. (2004) in this mini-
monograph.
Overview of Findings
The specific details of one aspect of the
HWG study (Hamadeh et al. 2002b) have
already been published, whereas several
others appear in this mini-monograph
(Baker et al. 2004; Goodsaid et al. 2004;
Chu et al. 2004; Waring et al. 2004). It is
anticipated that additional reports will also
be generated from our consortium when
final experiments and data analyses have
been conducted. In reviewing the experi-
mental data published previously and
in this mini-monograph, we can make 
a number of general comments and
conclusions regarding the outcome of the
work group’s studies.
In vivo studies. For clofibrate, study
results measured by traditional parameters
were as expected and in agreement with
those already published, although differ-
ences in the levels of biological response
induced in the two separate in vivo studies
for cloﬁbrate were suggested by variance in
the percent liver weight increases. At day 3
the increases in liver weight of treated ani-
mals compared with those in control ani-
mals were 15 and 3%, and at day 7 they
were 31 and 11% for the GSK and Abbott
Laboratory studies, respectively. Differences
in biological response were also supported
by observed differences in clinical chemistry
parameters and in the level of upregulation
of two well-characterized markers of clofi-
brate exposure, namely, cytochrome P450
(CYP)4A1 and acyl-CoA oxidase as meas-
ured on the Affymetrix platform. However,
other markers such as acyl-CoA hydrolase,
acyl-CoA transferase, and ApoA-IV, were
similarly regulated in the two studies, and
enzymatic content of acyl-CoA oxidase was
increased (though to somewhat different
extents) in both studies (Figure 2). 
Histopathological and clinical chemistry
observations on the methapyrilene-exposed
animals were consistent with expected toxici-
ties associated with methapyrilene treatment.
Speciﬁcally, signiﬁcant increases of enzyme
levels (asparate aminotransferase, alanine
aminotransferase, sorbitol dehydrogenase
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Table 2. Microarray platforms used by the HESI consortium.
Methapyrilene Cloﬁbrate
Company Microarray platform Company Microarray platform
Boehringer-Ingelheim Affymetrix Abbott  Laboratories Affymetrix
Pharmaceuticals, Inc.
AstraZeneca Affymetrix AstraZeneca Affymetrix
Pharmaceuticals, Inc. Pharmaceuticals, Inc.
F. Hoffman-LaRoche Affymetrix Aventis Pharmaceuticals Affymetrix
Novartis Pharmaceuticals Corp. Affymetrix Bristol-Myers Squibb Affymetrix
Pﬁzer Inc Affymetrix F. Hoffman-LaRoche Affymetrix
Schering AG Affymetrix Novartis AG Affymetrix
Wyeth-Ayerst Research Affymetrix Wyeth-Ayerst Research Affymetrix
Unilever Clontech GlaxoSmithKline Clontech
AstraZeneca Incyte Unilever Research Clontech
Pharmaceuticals, Inc.
National Institute of  NIEHS Chip U.S. Environmental Protection Clontech
Environmental Health Sciences Agency
RW Johnson PRI Molecular Dynamics AstraZeneca Incyte
Pharmaceuticals, Inc.
Bayer CropScience PHASE-1 RW Johnson PRI Molecular Dynamics
Boehringer-Ingelheim PHASE-1 SmithKline Beechama Molecular Dynamics
Pharmaceuticals, Inc.
Schering Plough Research PHASE-1 National Institute of  NIEHS Chip
Institute Environmental Health Sciences
Bayer CropScience PHASE-1
Boehringer-Ingelheim PHASE-1
Pharmaceuticals, Inc.
Schering Plough Research  PHASE-1
Institute
aNow GlaxoSmithKline.
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Figure 2. Acyl-CoA oxidase (ACOX) activity in livers from rats treated with clofibrate. Acyl-CoA oxidase
(ACOX) activity in rat liver samples from two in vivo studies expressed as percent of control levels: (A)
Abbott study; (B) GlaxoSmithKline study. Rats received clofibrate by oral gavage at low (25 mg/kg/day)
and high (250 mg/kg/day) doses for 1, 3, and 7 days. Data shown are the mean ± SD for each group (n = 4).
Figure contributed by Robert Jolly, Eli Lilly, and reproduced with permission.
**Signiﬁcant (p < 0.01) changes from control. Signiﬁcance was assessed using Student t test.were observed in the high-dose groups (100
mg/kg/day) at all the time points (1, 3, and 7
days) and drug-related microscopic changes,
including portal mononuclear inﬁltrate, peri-
portal hydropic degeneration, periportal
hepatocellular necrosis, and bile duct hyper-
plasia, were observed in the livers of male rats
treated with methapyrilene. 
Microarray gene expression analysis—
clofibrate studies. Differences in the probe
sets and annotations across platforms made
precise cross-platform comparisons chal-
lenging. However, changes in similar bio-
logical pathways were indicated on each of
the platforms run by the working group
members. In general, a dose-related
response was observed, with the low dose
demonstrating little deviation from control
levels of gene expression and evaluation of
differential gene expression from pooled
liver samples from rats treated with
high-dose (250 mg/kg/day) cloﬁbrate for 1,
3, or 7 days, demonstrating typical
PPAR-α–mediated responses associated
with established literature for this class of
compound (Amacher et al. 1997; Corton
et al. 2000; Gerhold et al. 2001; Latruffe
et al. 2001; Reddy et al. 1986). Affected
pathways included fatty acid metabolism
(e.g., acyl-CoA oxidase), cell proliferation
(e.g., topoisomerase II-α) and fatty acid
oxidation (e.g., CYP4A1). Gene expression
at the high dose supported the interpreta-
tion of a burst of cell proliferation, and
DNA repair during the ﬁrst 3 days of high-
dose exposure followed by a low level of
oxidative stress associated with increased
β-oxidation of fats (mitochondrial and per-
oxisomal), increased peroxisome prolifera-
tion, and protein folding stress responses
that partially but not completely subside
with continued dosing. 
The upregulation of a variety of cell
proliferation–associated genes began on or
before day 1 and peaked at some point
between days 3 and 7. By day 7, cell prolif-
eration genes were downregulated. The
chronology of these gene expression changes
agrees well with the histologic diagnoses of
mitotic ﬁgures in the tissue [see Baker et al.
(2004) in this mini-monograph).
The Affymetrix microarray platform
(speciﬁcally the RGU34A expression probe
array containing 8,799 probe sets from the
rat genome) was the most commonly used
platform for analyzing the clofibrate RNA
samples. Comparisons were thus con-
ducted for the Affymetrix data a) between
the RNA samples generated from a single
in-life study, and b) across all the RNA
samples. Across all probes sets, agreement
between contributors and within samples
from a single in vivo study was good, with
greater than 92% concordance for samples
originating from one of the in vivo study
laboratories, and greater than 96% for sam-
ples from the other laboratory. To be con-
sidered “concordant,” a probe set showed
either no change or no discrepancy in the
direction of change for all data sets. Less
apparent agreement was observed for
changes above or below a certain threshold
of fold-change for all data sets. For example,
only four probe sets were identified as
upregulated > 5-fold in all data sets on sam-
ples from a single in vivo laboratory. This
result may be explained in part by the use of
different data capture algorithms by the
contributors. It can also be attributed to the
somewhat arbitrary nature of selecting a
particular fold-change cutoff level where
pooled samples were used. This is an
inescapable outcome when data are pre-
sented that are derived from pooled sample
comparisons, as the number of biological
replicates in a pool is effectively one, mak-
ing statistical analysis impossible. In addi-
tion, cutoff criterion might be too stringent,
as a larger number of probe sets were regu-
lated in the same direction across the data
sets regardless of thresholds.
Microarray gene expression analysis–
methapyrilene studies. In the comparison of
RNA samples from methapyrilene-treated
rats, analyses were performed at five sites
using an Affymetrix platform and at ﬁve sites
using either a membrane or glass slide cDNA
microarray platform. Agreement was found
across all platforms with reasonable but vary-
ing degrees of congruence in the results.
These ﬁndings are discussed in more detail
in an article published on cDNA platform
results (Hamadeh et al. 2002b) and in this
mini-mongraph in an article on Affymetrix
array results (Waring et al. 2004). In general,
these two articles show that analysis of RNA
samples from separate studies conducted in
different laboratories and analyzed by differ-
ent methods ultimately revealed the same
affected biological pathways and hence the
same risk determinants.
Results of gene expression analysis on
the NIEHS cDNA platform of RNA from
livers of rats treated with the high dose of
methapyrilene for 7 days at both of the
in vivo study sites showed good agreement.
Scientists from NIEHS also reviewed the
microscopic observations resulting from
methapyrilene treatments and collected
additional data, such as serum enzyme lev-
els and body and organ weights. The micro-
scopic data were entered into a numerical
model, the output of which was compared
with the clustering outcomes of the gene
expression data showing remarkable agree-
ment between the outputs of the two analy-
ses. Finally, analysis of results generated
from Affymetrix arrays [see Waring et al.
(2004) in this mini-monograph] showed
that low-dose–treated animals could be dis-
tinguished from high-dose and control ani-
mals, a differentiation that could not be
made based on histology.
qRT-PCR studies. In a small number of
cases, contradictory data were obtained
from different platforms running samples
from the cloﬁbrate study. Two of these dis-
crepancies (Caldesmon and Pctaire) were
investigated further using in silico sequence
analysis and qRT–PCR analyses of the
genes. In both cases, cDNA platform
results showed decreases in expression lev-
els for the 7-day high-dose pooled samples
compared with those for controls. In con-
trast, the Affymetrix platform showed
increases in expression levels compared
with those for controls. The outcome of
the studies, which are described in detail by
Goodsaid et al. (2004) elsewhere in this
mini-monograph, confirmed that the
source of the discrepancies was errors in the
sequences of the gene as defined by
UniGene (http://www.ncbi.nih.gov/entrez/
query.fcgi?db=unigene).
Commentary 
The Hepatotoxicity Working Group
selected two well-characterized chemicals for
analysis, as this would permit us to deter-
mine whether the in vivo exposures had
been effectual and allow the group to cor-
roborate clinical, histopathological, and gene
expression data by comparison with pub-
lished studies. Histopathology, clinical
chemistry, and organ weight changes were
indeed consistent with previously reported
effects of these agents, albeit with some dif-
ferences between sites, as evidenced by dis-
crepancies in liver weights and other clinical
chemistry parameters. Analysis of gene
expression also indicated that changes in
mRNA levels for known transcriptional
reporters for these compounds had
occurred, although there were discrepancies
in some individual genes [as discussed, for
example, in the accompanying article by
Waring et al. (2004)]. The discrepancies
between sites and between platforms
observed for individual transcripts could be
attributed mostly to differences in RNA
labeling protocols, sequence differences on
different platforms, and statistical analysis
tools. qRT-PCR studies demonstrated that
selection and characterization of correct
probes on microarrays are essential if
microarray data are to be perceived as being
robust and consistent [as discussed in the
accompanying article by Goodsaid et al.
(2004]); such discrepancies will be alleviated
with time as the accuracy of gene sequences
and annotations evolves. It will also be
important to understand the relationship
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in protein expression; proteome analysis on
samples derived from this collaboration is
currently in progress. Perhaps more impor-
tant than individual genes, however, is the
accurate identiﬁcation of affected biological
pathways. This outcome, which was consis-
tent between laboratories, is essential for the
application of toxicogenomics in the under-
standing of toxic mechanisms. Thus, to the
extent that data analysis has been completed,
this collaboration has revealed that RNA
samples generated from rat studies con-
ducted for the same compound in different
laboratories and analyzed using different
microarray platforms can yield comparable
results regarding the affected biological
pathways and key pathway-associated genes.
It is not yet clear, however, how these data
can be applied to risk assessment; this is the
ultimate aim of the HESI Technical
Committee on the Application of Genomics
to Mechanism-Based Risk Assessment.
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